Orforglipron: Primary completion and completion of P3 ATTAIN-2 trial (NCT05872620) for obesity in Aug 2025 (Eli Lilly) - Feb 7, 2025 - Q4 2024 Results: Primary completion and completion of P3 ATTAIN-MAINTAIN trial (NCT06584916) for obesity in Jan 2026
Trial completion date • Trial primary completion date • Obesity
|